Advertisement Biomoda starts collaboration with New Mexico - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Biomoda starts collaboration with New Mexico

Biomoda has reached an agreement with New Mexico Tech to collaborate on clinical studies and the development of specialized image recognition technology as part of the company's commercialization of its assay for the early detection of lung cancer.

Biomoda’s patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive, according to the company.

Daniel Lopez, president of New Mexico Tech, said: “This new R&D collaboration between Biomoda and New Mexico Tech will enable university researchers and students to directly participate in the testing and development of cutting-edge technology which will soon be deployed in the fight against cancer. This new joint venture forged between a public university and a private business promises to be a win-win situation for all involved.”

John Cousins, president of Biomoda, said: “I am particularly pleased to announce our partnership with such a strong research and engineering partner as New Mexico Tech as we move towards commercialization of Biomoda’s early cancer diagnostic technology. The scientists at New Mexico Tech offer a wide range of expertise in biomedical and engineering research programs that will be applied immediately in development of engineering technology for image recognition that is targeted at broad-based screening of large populations for lung cancer.”